In the United States, almost 1.5 million people are reported to be affected by Parkinson’s disease (PD), wherein 60,000 patients continue to be diagnosed with the condition every year, costing the U.S. economy US$14 billion on an annual basis in the direct and indirect expenses.
At present, 302 products are being actively developed in the therapeutic pipeline of Parkinson’s disease over a number of stages. However, the mechanisms of action applied on the existing products compared to the ones in the pipeline shows severe differences. The existing symptomatic treatments employed for PD target neuromodulatory receptors; whereas, the current product pipeline features a widespread array of neuroprotective therapies focusing on dysfunctional disease procedures.
The availability of ninety first-in-class products that holds 37% of the overall therapies in pipeline is one of the major reason behind the diversity in the MoA for both, existing products and pipeline products. Since, the global PD industry is driven by first-in-class products compared to the non-first-in-class ones; the development of this market is widely impacted by this factor. Although the first-in-class products and therapies have indicated high abrasion rate in past, they have the potential to modify the global PD treatment market for good.
Browse the full Press Release of Parkinson’s Disease Market : http://www.mrrse.com/parkinson-disease-therapeutics-market-report
As the global market for Parkinson’s disease is rising at a rapid pace, let’s take a look at the future prospects the market is going to deal with:
· The overall revenue generated from sales in the PD markets of the U.S., Germany, France, Italy, the U.K., Spain, and Japan is expected to register a slight decline from around US$2.7 billion in 2010 to an estimate of US$2.6 billion by 2020.
· The dominant dopamine agonists, ropinirole and pramipexole, are expected to trigger the sales significantly. The increasing usage of Agilect, the MAO-B inhibitor, and the resurgence of UCB’s Leganto/Neupro in the U.S. market with an even wider employment in the European market are also projected to drive the market growth.
· In spite of the increased uptake of some key therapies currently functional in the market and the announcement to launch 3 new agents (GlaxoSmithKline’s IPX-066, Newron Pharmaceuticals’ safinamide, and Kyowa Hakko Kirin’s istradefylline) by 2020, the sales of current agents and their impact on the market of emerging therapies is likely to be suppressed by generic competition.
IPX-066 and safinamide (to a lesser extent) are expected to support the market growth moderately, as both are set to compete with established agents within their respective drug classes, and with those that are commonly utilized for the patients. Istradefylline, which is the first-in-class agent in the group, is likely to benefit from the usage in the motor response complications management arising from use of levodopa, but its overall effect is predicted to be modest owing to its expected launch in Japan only.